Discussing the AIM study (Adiposity, Influenza and Men)

University of Calgary-Faculty of Kinesiology

A common experience to the influenza vaccine: wouldn’t it be nice!

Dr. Patricia Doyle-Baker discusses the AIM study, the issues and the results.

We no longer need to be convinced based on the depth and breadth of the evidence that obesity is a risk factor for many disease conditions. Perhaps not as well-known, is the association between obesity and severe influenza outcomes. According to Sheridan et al. (2012), this association was well documented in several epidemiological studies following the 2009 H1N1 influenza pandemic. This growing body of literature suggests that not only do overweight and obese individuals experience a greater proportion of negative outcomes as a result of exposure (Louie et al., 2011, Van Kerkhove et al., 2011), but also vaccination response differs in young and middle-aged adults (Alberta Health, 2014).

Vaccination Response

Differences in vaccination response have been documented beyond age and underlying disease (Ohmit et al., 2013). For example, the volume of physical activity was found to influence both the risk of upper respiratory tract infections (Neiman, 1994), as well as antibody production to the influenza vaccine (Kohut et al., 2002). This information led us to investigate the potential role of emerging lifestyle factors on the effectiveness of immunization in young men. We surmised in the AIM (Adiposity, Influenza, Men) study that protection against the influenza virus would be similar among most participants but that increases in adiposity and lower levels of physical activity would reduce the effectiveness of vaccination (Stewart et al., 2018).


In immunology, antibodies mediate protection against infection by interfering with antigen (a virus or foreign substance) binding to host-cell receptors. During an infection or immunization, antigens enter the blood, and the immune system starts to produce antibodies in response. Most individuals develop detectable antibodies within 3 weeks; this time period is referred to as seroconversion.


To achieve seroprotection, the antibody level must go above a specific threshold or cut-off level. The cut-off level is usually defined as the antibody level at which the probability of clinical protection is 50%, if exposed to infection. An antibody level or titer of ≥40 corresponds to 50% protection (Coudeville et al., 2010), but this may vary by influenza A subtype and the individual’s (host) age.

Influenza Subtype

The subtype of the influenza virus, for example A/H1N1, is determined by proteins. These proteins are embedded in the lipid membrane of the influenza virion, which is roughly spherical in shape. The inserted proteins are linked to sugars – known as hemagglutinin (HA) and neuraminidase (NA). Virus protection should correlate with the antibody titers to the HA surface proteins. This is measured by the HA inhibition assay (HAI), the primary method for determining quantitative antibody titers for the influenza virus (Zacour et al., ‎2016). In the AIM study the HAI assays for each influenza strain were performed in duplicate by the Canadian Centre for Vaccinology.

Trivalent Influenza Vaccine (TIV)

The influenza A virus is constantly changing and is generally responsible for seasonal flu epidemics. Seasonal influenza vaccines are trivalent (TIV) because they contain three circulating subtypes (A/H3N2, A/H1N1 and B strains) that are updated yearly to best predict the strains circulating in the community. Inactivated influenza vaccines are the most commonly used and are standardized according to the quantity of the major surface antigen (Cox, 2013). During the 2014/2015 season TIV was produced by GlaxoSmithKline under the Fluviral® name with subtypes A/California/7/2009 (H1N1) pdm09-like virus, A/Texas/50/2012 (H3N2)-like virus, and B/Massachusetts/2/2012-like virus (Yamagata lineage).

AIM Study

Our prospective design used a rolling recruitment with a duration of 3 months beginning at the start of the autumn flu vaccination period. A 131 Albertan males (age 18-35 yrs.) responded to the online survey posted on popular social media platforms and a 125 met inclusion criteria. At the baseline session percent body fat (%BF) was measured using dual X-ray absorptiometry imagining (Hologic Discovery QDR Series AX Bedford, Massachusetts) and physical activity level was determined from the Godin Leisure Time Physical Activity questionnaire (Godin and Shepard, 1997). Following the fasting blood draw, participants (n=76) were asked to attend either a provincial vaccination clinic or the university student wellness centre to receive the 2014/15 inactivated TIV and return 4-weeks later for post vaccination blood draw (n=45; median age 23, %BF range: 9.4-31.5).


Our primary outcome was seroconversion, defined as at least four-fold increase in antibody titer pre-to post vaccination. Using this measure, participants either seroconverted or failed to seroconvert for each of the three influenza strains included in the TIV (Table 1). Seroprotection was our secondary outcome measure, defined as an antibody titre of at least 160. No differences in median %BF were associated with seroconversion rates in participants and the median physical activity score was higher among those that did not seroconvert to the vaccine. Significant differences were found for the A/Texas strain (p < 0.01) with a mean physical activity score for non-seroconverters of 81 versus 46 in the seroconverting group. While mean physical activity scores were higher in non-seroconverters for all strains, no statistically significant differences were observed for A/California and B/Massachusetts strains (Table 2).

The AIM study (Adiposity, Influenza and Men) results


The most interesting result was the trend towards lower vaccine response in these young men who were highly physically active beyond the recommended 150 minutes of moderate to vigorous intensity of activity per week for adults aged 18-64 years (Canadian Society for Exercise Physiology, 2011). Our sample however, represented a subset of the North American population with lower adiposity (mean BF 17.1%) when compared to a similar age range (20-39 yr.) and body fat (mean BF 26.1%) (Li et al., 2009). This is all somewhat surprising; however, we must be cautious given the lower than anticipated return rate (59%), the lack of previous influenza vaccination (66%) and the exploratory nature of the study.

Public Health Perspective

From a public health perspective, it ‘would be nice’ if a common experience occurred with the influenza vaccine. However, our study suggests that young very active males may experience less protection, and if so, steps should be taken to consider more than just age and disease when classifying influenza “high risk” groups. The inclusion in future research of a direct measure of aerobic capacity alongside body composition and physical activity volume would better address the complexity of their biological interface. Regardless of this, it goes without saying that yearly influenza vaccination remains the best strategy for the prevention of influenza virus-related disease and reduction of disease severity and mortality.


Please enter your comment!
Please enter your name here